ARTICLE | Clinical News
Selumetinib: Phase I data
June 1, 2015 7:00 AM UTC
Data from 41 patients with solid tumors in an open-label, dose-escalation, UK Phase I trial showed that once-daily oral vandetanib plus oral selumetinib led to 4 cases of stable disease in patients wi...